Nov 18, 2026 | Announcements, Asthma, Biosimilars, Cost Savings, Drug costs, MedBen Rx, Pharmacy, Rx Costs, Uncategorized
Effective January 1, 2027, MedBen Rx will add Omlyclo, a biosimilar to Xolair, to the formulary for clients participating in its biosimilar program. Omlyclo is used to treat certain patients with allergic asthma, nasal polyps, or chronic hives and to help reduce the...
Sep 14, 2026 | Drug costs, MedBen Rx, Pharmacy, Prescription, Rebates, Rx Costs
A large rebate can look like a bargain, but often it only offsets a higher list price. Manufacturer rebates are typically a percentage of list price, so raising the list price makes the rebate look bigger without reducing what the plan pays. That is why rebate size is...
Sep 14, 2026 | Client Report, Cost management, Health care costs, Rx Costs, Trend
Employers heading into 2027 face another year of steep health care cost increases. Matching national trend still means absorbing a large increase. The more useful target is staying below trend — and doing it repeatedly. The difference can add up quickly. From 2021...
Aug 17, 2026 | Drug costs, Pharmacy Benefits Manager (PBM), Rx Costs, Survey
The share of employers using one of the three major pharmacy benefit managers — Optum Rx, CVS Caremark, or Express Scripts — fell from 63.4% in 2025 to 54.3% in 2026, according to the National Alliance of Healthcare Purchaser Coalitions’ Pulse of the Purchaser survey....
Aug 3, 2026 | Biosimilars, Cost Savings, Drug costs, Pharmacy, Prescription, Rx Costs, Savings, Specialty Drugs
Specialty drug costs are projected to jump another 32% by 2028, according to the Pharmacy Strategies Group. While greater utilization remains the primary driver, lower-cost biosimilars can help pharmacy plans offset the increase. Biosimilars’ overall market share...
Jul 3, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Client Report, Drug costs, Formularies, MedBen Rx, Rx Costs, Specialty Drugs, Spending, Transparency
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....